RESUMEN
BACKGROUND: Acute and chronic brain damage in type 2 diabetes mellitus (DM) determines the need to investigate the neuroprotective potential of glucose-lowering drugs. The purpose was to directly compare the neuroprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) with different duration of action and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in type 2 diabetic rats with and without stroke. METHODS: DM was modelled using high-fat diet and nicotinamide+streptozotocin protocol. The following groups (n = 15 each) were formed: DM without treatment, treatment with liraglutide, dulaglutide, canagliflozin as well as control group without DM and treatment. After 8 weeks, 10 rats from each group underwent middle cerebral artery occlusion. In the reperfusion period neurological deficit, neuroglial damage markers and brain necrosis were evaluated. Brain slices from the remaining 5 animals in each group were histologically examined for microglial activation and neuronal damage. RESULTS: Brain damage was similar in "DM" and "Control" (17.53 [14.23; 26.58] and 15.87 [13.40; 22.68] % of total brain volume, respectively). All study drugs diminished damage volume comparing with "DM" and "Control" whereas the necrosis volume in "DM+Liraglutide" was smaller than in "DM+Canagliflozin" and did not significantly differ from "DM+Dulaglutide" (2.9 [1.83; 4.71], 6.17 [3.88; 8.88] and 4.57 [3.27; 7.90] %). The neurological deficit was more prominent in "DM" than in "Control", while all the drugs demonstrated similar positive effect. Neurofilament light chains (NLC) did not differ between "DM" and "Control". Dulaglutide and canagliflozin caused a marked decrease in NLC. Protein S100BB level was similar in "DM" and "Control". Liraglutide caused the largest S100BB decrease, while canagliflozin did not influence it. In chronic brain ischaemia, all drugs increased the number of normal neurons, but GLP-1RAs had a more pronounced effect. DM was accompanied by increased number of activated microglial cells in Cornu Ammonis (CA)1 hippocampal region. Both GLP-1RAs reduced the number of Iba-1-positive cells, with dulaglutide being more effective than liraglutide, whereas canagliflozin did not affect this parameter. CONCLUSIONS: GLP-1RAs and SGLT-2i have neuroprotective properties against acute and chronic brain damage in diabetic rats, although the infarct-limiting effect of GLP-1RAs may be more pronounced. GLP-1RAs and SGLT-2i exert their protective effects by directly influencing neuronal survival, whereas GLP-1RAs also affect microglia.
Asunto(s)
Diabetes Mellitus Experimental , Diabetes Mellitus Tipo 2 , Receptor del Péptido 1 Similar al Glucagón , Microglía , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Animales , Inhibidores del Cotransportador de Sodio-Glucosa 2/farmacología , Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico , Diabetes Mellitus Experimental/patología , Diabetes Mellitus Experimental/complicaciones , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/tratamiento farmacológico , Microglía/efectos de los fármacos , Microglía/metabolismo , Microglía/patología , Masculino , Receptor del Péptido 1 Similar al Glucagón/agonistas , Receptor del Péptido 1 Similar al Glucagón/metabolismo , Ratas , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/patología , Ratas Wistar , Daño Encefálico Crónico/prevención & control , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/patología , Liraglutida/farmacología , Liraglutida/uso terapéutico , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/uso terapéuticoRESUMEN
Subarachnoid hemorrhage (SAH) is a catastrophic form of stroke responsible for significant morbidity and mortality. Oxidative stress, inflammation, and neuronal apoptosis are important in the pathogenesis of early brain injury (EBI) following SAH. Preconditioning exercise confers neuroprotective effects, mitigating EBI; however, the basis for such protection is unknown. We investigated the effects of preconditioning exercise on brain damage and sensorimotor function after SAH. Male rats were assigned to either a sham-operated (Sham) group, exercise (Ex) group, or no-exercise (No-Ex) group. After a 3-week exercise program, they underwent SAH by endovascular perforation. Consciousness level, neurological score, and sensorimotor function were studied. The expression of nuclear factor erythroid 2 p45-related factor 2 (Nrf2), heme oxygenase 1 (HO-1), 4-hydroxynonenal (4HNE), nitrotyrosine (NT), ionized calcium-binding adaptor molecule 1 (Iba1), tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 1ß (IL-1ß), 14-3-3γ, p-ß-catenin Ser37, Bax, and caspase-3 were evaluated by immunohistochemistry or western blotting. The terminal deoxynucleotidyl transferase-mediated biotinylated dUTP nick end labeling (TUNEL) assay was also performed. After SAH, the Ex group had significantly reduced neurological deficits, sensorimotor dysfunction, and consciousness disorder compared with the No-Ex group. Nrf2, HO-1, and 14-3-3γ were significantly higher in the Ex group, while 4HNE, NT, Iba1, TNF-α, IL-6, IL-1ß, Bax, caspase-3, and TUNEL-positive cells were significantly lower. Our findings suggest that preconditioning exercise ameliorates EBI after SAH. The expression of 4HNE and NT was reduced by Nrf2/HO-1 pathway activation; additionally, both oxidative stress and inflammation were reduced. Furthermore, preconditioning exercise reduced apoptosis, likely via the 14-3-3γ/p-ß-catenin Ser37/Bax/caspase-3 pathway.
Asunto(s)
Daño Encefálico Crónico/prevención & control , Neuronas/patología , Condicionamiento Físico Animal , Hemorragia Subaracnoidea/complicaciones , Proteínas 14-3-3/fisiología , Animales , Apoptosis , Daño Encefálico Crónico/diagnóstico por imagen , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/metabolismo , Citocinas/biosíntesis , Citocinas/genética , Modelos Animales de Enfermedad , Regulación de la Expresión Génica , Procesamiento de Imagen Asistido por Computador , Etiquetado Corte-Fin in Situ , Masculino , Proteínas del Tejido Nervioso/biosíntesis , Proteínas del Tejido Nervioso/genética , Enfermedades Neuroinflamatorias/etiología , Enfermedades Neuroinflamatorias/metabolismo , Enfermedades Neuroinflamatorias/prevención & control , Estrés Oxidativo , Condicionamiento Físico Animal/fisiología , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Transducción de Señal , Factores de Tiempo , Microtomografía por Rayos XRESUMEN
INTRODUCTION: The objective is to analyze the clinical diagnosis and treatment of children with rescindable posterior encephalopathy syndrome (PRES) and intracranial hemorrhage (ICH) to improve the pediatrician's understanding of PRES combined with ICH in children. PATIENT CONCERNS AND DIAGNOSIS: After liver transplantation, the patient developed symptoms of epilepsy and coma. Meanwhile, massive necrosis of acute cerebral infarction and small hemorrhage was observed in the left cerebellar hemisphere and left occipital lobe, respectively. The above symptoms were initially diagnosed as PRES. INTERVENTIONS AND OUTCOMES: After adjusting the anti-rejection drug regimen, it was found that the child's neurological symptoms were relieved, and the limb motor function gradually recovered during follow-up. Imaging examination showed significant improvement on abnormal signals in brain. CONCLUSION: In general, children with PRES may further develop ICH and contribute to a poor prognosis. Early diagnosis, detection of risk factors and timely adjustment of medication regimen are the keys to prevent irreversible brain damage.
Asunto(s)
Conductos Biliares/anomalías , Atresia Biliar/cirugía , Infarto Cerebral , Terapia de Inmunosupresión , Hemorragias Intracraneales , Síndrome de Leucoencefalopatía Posterior , Ajuste de Riesgo/métodos , Atresia Biliar/diagnóstico , Atresia Biliar/etiología , Encéfalo/diagnóstico por imagen , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/prevención & control , Infarto Cerebral/diagnóstico , Infarto Cerebral/etiología , Preescolar , Diagnóstico Precoz , Humanos , Terapia de Inmunosupresión/efectos adversos , Terapia de Inmunosupresión/métodos , Hemorragias Intracraneales/diagnóstico , Hemorragias Intracraneales/etiología , Trasplante de Hígado/métodos , Imagen por Resonancia Magnética/métodos , Masculino , Síndrome de Leucoencefalopatía Posterior/diagnóstico , Síndrome de Leucoencefalopatía Posterior/etiología , Síndrome de Leucoencefalopatía Posterior/fisiopatología , Síndrome de Leucoencefalopatía Posterior/terapia , Tomografía Computarizada por Rayos X/métodosRESUMEN
Studies from our lab demonstrated that 1 × 105 intra-arterial mesenchymal stem cells (IA MSCs) at 6 h following ischemic stroke are efficacious owing to its maximum homing due to elevated stromal derived factor 1 (SDF1) in the tissue. Further, IA MSCs could abate the infarct progression, improve functional outcome, and decrease expression of calcineurin by modifying neuronal Ca2+ channels following ischemic stroke. Since stroke pathology also encompasses acidosis that worsens the condition; hence, the role of acid sensing ion channels (ASICs) in this context could not be overlooked. ASIC1a being the major contributor towards acidosis triggers Ca2+ ions overload which progressively contributes towards exacerbation of neuronal injury following ischemic insult. Inflammasome involvement in ischemic stroke is well reported as activated ASIC1a increases the expression of inflammasome in a pH-dependent manner to trigger inflammatory cascade. Hence, the current study aimed to identify if IA MSCs can decrease the production of inflammasome by attenuating ASIC1a expression to render neuroprotection. Ovariectomized Sprague Dawley (SD) rats exposed to middle cerebral artery occlusion (MCAo) for 90 min were treated with phosphate-buffered saline (PBS) or 1 × 105 MSCs IA at 6 h to check for the expression of ASIC1a and inflammasome in different groups. Inhibition studies were carried out to explore the underlying mechanism. Our results demonstrate that IA MSCs improves functional outcome and oxidative stress parameters, and decreases the expression of ASIC1a and inflammasomes in the cortical brain region after ischemic stroke. This study offers a preliminary evidence of the role of IA MSCs in regulating inflammasome by modulating ASIC1a.
Asunto(s)
Canales Iónicos Sensibles al Ácido/fisiología , Infarto de la Arteria Cerebral Media/terapia , Inflamasomas/metabolismo , Trasplante de Células Madre Mesenquimatosas/métodos , Proteínas del Tejido Nervioso/fisiología , Amilorida/uso terapéutico , Animales , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/prevención & control , Femenino , Infarto de la Arteria Cerebral Media/complicaciones , Infarto de la Arteria Cerebral Media/inmunología , Infarto de la Arteria Cerebral Media/metabolismo , Inyecciones Intraarteriales , Células Madre Mesenquimatosas/fisiología , Ovariectomía , Ratas , Ratas Sprague-Dawley , Prueba de Desempeño de Rotación con Aceleración Constante , Trastornos Somatosensoriales/etiología , Trastornos Somatosensoriales/prevención & controlRESUMEN
Traumatic brain injury (TBI) accounts for significant global health burden. Effects of TBI can become chronic even following mild injury. There is a need to develop effective therapies to attenuate the damaging effects of TBI and improve recovery outcomes. This literature review using a priori criteria (PROSPERO; CRD42018100623) summarized 43 studies between January 1998 and July 2019 that investigated nutritional interventions (NUT) delivered with the objective of altering neurophysiological (NP) outcomes following TBI. Risk of bias was assessed for included studies, and NP outcomes recorded. The systematic search resulted in 43 of 3,748 identified studies met inclusion criteria. No studies evaluated the effect of a NUT on NP outcomes of TBI in humans. Biomarkers of morphological changes and apoptosis, oxidative stress, and plasticity, neurogenesis, and neurotransmission were the most evaluated NP outcomes across the 43 studies that used 2,897 animals. The risk of bias was unclear in all reviewed studies due to poorly detailed methodology sections. Taking these limitations into account, anti-oxidants, branched chain amino acids, and ω-3 polyunsaturated fatty acids have shown the most promising pre-clinical results for altering NP outcomes following TBI. Refinement of pre-clinical methodologies used to evaluate effects of interventions on secondary damage of TBI would improve the likelihood of translation to clinical populations.
Asunto(s)
Daño Encefálico Crónico/prevención & control , Lesiones Traumáticas del Encéfalo/dietoterapia , Aminoácidos de Cadena Ramificada/administración & dosificación , Aminoácidos de Cadena Ramificada/uso terapéutico , Animales , Antioxidantes/administración & dosificación , Antioxidantes/uso terapéutico , Biomarcadores , Daño Encefálico Crónico/etiología , Lesiones Traumáticas del Encéfalo/complicaciones , Restricción Calórica , Creatina/administración & dosificación , Creatina/uso terapéutico , Dieta Cetogénica , Suplementos Dietéticos , Medicamentos Herbarios Chinos/administración & dosificación , Medicamentos Herbarios Chinos/uso terapéutico , Ayuno , Ácidos Grasos Omega-3/administración & dosificación , Ácidos Grasos Omega-3/uso terapéutico , Femenino , Predicción , Humanos , Masculino , Ratones , Ratones Endogámicos ICR , Ratas , Ratas Sprague-Dawley , Ratas Wistar , Proyectos de InvestigaciónRESUMEN
Stroke severely impairs quality of life and has a high mortality rate. On the other hand, dietary docosahexaenoic acid (DHA) prevents neuronal damage. In this review, we describe the effects of dietary DHA on ischemic stroke-associated neuronal damage and its role in stroke prevention. Recent epidemiological studies have been conducted to analyze stroke prevention through DHA intake. The effects of dietary intake and supply of DHA to neuronal cells, DHA-mediated inhibition of neuronal damage, and its mechanism, including the effects of the DHA metabolite, neuroprotectin D1 (NPD1), were investigated. These studies revealed that DHA intake was associated with a reduced risk of stroke. Moreover, studies have shown that DHA intake may reduce stroke mortality rates. DHA, which is abundant in fish oil, passes through the blood-brain barrier to accumulate as a constituent of phospholipids in the cell membranes of neuronal cells and astrocytes. Astrocytes supply DHA to neuronal cells, and neuronal DHA, in turn, activates Akt and Raf-1 to prevent neuronal death or damage. Therefore, DHA indirectly prevents neuronal damage. Furthermore, NDP1 blocks neuronal apoptosis. DHA, together with NPD1, may block neuronal damage and prevent stroke. The inhibitory effect on neuronal damage is achieved through the antioxidant (via inducing the Nrf2/HO-1 system) and anti-inflammatory effects (via promoting JNK/AP-1 signaling) of DHA.
Asunto(s)
Daño Encefálico Crónico/prevención & control , Ácidos Docosahexaenoicos/uso terapéutico , Accidente Cerebrovascular Isquémico/dietoterapia , Degeneración Nerviosa/prevención & control , Accidente Cerebrovascular/prevención & control , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/farmacocinética , Antiinflamatorios/uso terapéutico , Antioxidantes/administración & dosificación , Antioxidantes/farmacocinética , Antioxidantes/uso terapéutico , Apoptosis/efectos de los fármacos , Disponibilidad Biológica , Transporte Biológico , Barrera Hematoencefálica , Daño Encefálico Crónico/etiología , Grasas de la Dieta/administración & dosificación , Grasas de la Dieta/farmacocinética , Grasas de la Dieta/uso terapéutico , Ácidos Docosahexaenoicos/administración & dosificación , Ácidos Docosahexaenoicos/metabolismo , Ácidos Docosahexaenoicos/farmacocinética , Ácidos Docosahexaenoicos/farmacología , Proteínas de Unión a Ácidos Grasos/fisiología , Aceites de Pescado/administración & dosificación , Aceites de Pescado/farmacocinética , Humanos , Incidencia , Accidente Cerebrovascular Isquémico/complicaciones , Accidente Cerebrovascular Isquémico/epidemiología , Lípidos de la Membrana/metabolismo , Ratones , Proteínas de Neoplasias/fisiología , Proteínas del Tejido Nervioso/metabolismo , Neuronas/metabolismo , Aceites de Plantas/administración & dosificación , Aceites de Plantas/farmacocinética , Transducción de Señal/efectos de los fármacos , Simportadores/deficiencia , Simportadores/fisiología , Ácido alfa-Linolénico/farmacocinéticaRESUMEN
The intestinal microbiome is emerging as a critical factor in health and disease. The microbes, although spatially restricted to the gut, are communicating and modulating the function of distant organs such as the brain. Stroke and other neurological disorders are associated with a disrupted microbiota. In turn, stroke-induced dysbiosis has a major impact on the disease outcome by modulating the immune response. In this review, we present current knowledge on the role of the gut microbiome in stroke, one of the most devastating brain disorders worldwide with very limited therapeutic options, and we discuss novel insights into the gut-immune-brain axis after an ischemic insult. Understanding the nature of the gut bacteria-brain crosstalk may lead to microbiome-based therapeutic approaches that can improve patient recovery.
Asunto(s)
Eje Cerebro-Intestino , Disbiosis/complicaciones , Microbioma Gastrointestinal , Accidente Cerebrovascular/microbiología , Envejecimiento , Animales , Antibacterianos/uso terapéutico , Traslocación Bacteriana , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/prevención & control , Isquemia Encefálica/etiología , Isquemia Encefálica/microbiología , Isquemia Encefálica/terapia , Eje Cerebro-Intestino/efectos de los fármacos , Células Dendríticas/inmunología , Modelos Animales de Enfermedad , Disbiosis/inmunología , Disbiosis/fisiopatología , Ácidos Grasos Volátiles/metabolismo , Fermentación , Microbioma Gastrointestinal/efectos de los fármacos , Motilidad Gastrointestinal , Humanos , Infarto/patología , Inflamación , Intestinos/irrigación sanguínea , Ratones , Norepinefrina/metabolismo , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/terapia , Linfocitos T Reguladores/inmunologíaRESUMEN
Hypoxic-ischemic encephalopathy (HIE) is still a major cause of neonatal death and disability as therapeutic hypothermia (TH) alone cannot afford sufficient neuroprotection. The present study investigated whether ventilation with molecular hydrogen (2.1% H2) or graded restoration of normocapnia with CO2 for 4 h after asphyxia would augment the neuroprotective effect of TH in a subacute (48 h) HIE piglet model. Piglets were randomized to untreated naïve, control-normothermia, asphyxia-normothermia (20-min 4%O2-20%CO2 ventilation; Tcore = 38.5 °C), asphyxia-hypothermia (A-HT, Tcore = 33.5 °C, 2-36 h post-asphyxia), A-HT + H2, or A-HT + CO2 treatment groups. Asphyxia elicited severe hypoxia (pO2 = 19 ± 5 mmHg) and mixed acidosis (pH = 6.79 ± 0.10). HIE development was confirmed by altered cerebral electrical activity and neuropathology. TH was significantly neuroprotective in the caudate nucleus but demonstrated virtually no such effect in the hippocampus. The mRNA levels of apoptosis-inducing factor and caspase-3 showed a ~10-fold increase in the A-HT group compared to naïve animals in the hippocampus but not in the caudate nucleus coinciding with the region-specific neuroprotective effect of TH. H2 or CO2 did not augment TH-induced neuroprotection in any brain areas; rather, CO2 even abolished the neuroprotective effect of TH in the caudate nucleus. In conclusion, the present findings do not support the use of these medical gases to supplement TH in HIE management.
Asunto(s)
Asfixia Neonatal/terapia , Daño Encefálico Crónico/prevención & control , Dióxido de Carbono/uso terapéutico , Hidrógeno/uso terapéutico , Hipotermia Inducida , Hipoxia-Isquemia Encefálica/terapia , Neuroprotección/efectos de los fármacos , Fármacos Neuroprotectores/uso terapéutico , Acidosis/sangre , Acidosis/etiología , Acidosis/prevención & control , Administración por Inhalación , Animales , Animales Recién Nacidos , Factor Inductor de la Apoptosis/biosíntesis , Factor Inductor de la Apoptosis/genética , Asfixia Neonatal/complicaciones , Asfixia Neonatal/tratamiento farmacológico , Daño Encefálico Crónico/etiología , Factor Neurotrófico Derivado del Encéfalo/biosíntesis , Factor Neurotrófico Derivado del Encéfalo/genética , Dióxido de Carbono/administración & dosificación , Dióxido de Carbono/toxicidad , Caspasa 3/biosíntesis , Caspasa 3/genética , Núcleo Caudado/patología , Corteza Cerebral/metabolismo , Corteza Cerebral/patología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Electroencefalografía , Potenciales Evocados Visuales/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Hipocampo/patología , Hidrógeno/administración & dosificación , Hidrógeno/análisis , Hipoxia-Isquemia Encefálica/complicaciones , Hipoxia-Isquemia Encefálica/tratamiento farmacológico , Hipoxia-Isquemia Encefálica/patología , Proteínas del Tejido Nervioso/biosíntesis , Proteínas del Tejido Nervioso/genética , Fármacos Neuroprotectores/administración & dosificación , Especificidad de Órganos , Distribución Aleatoria , PorcinosRESUMEN
OBJECTIVE: The RECO flow restoration (FR) device is a new stent retriever designed for rapid flow restoration in acute ischemic stroke (AIS) caused by large vessel occlusion (LVO). Here, the authors compared the efficacy and safety of the RECO device with the predicate Solitaire FR stent retriever. METHODS: The RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study (REDIRECT) was a multicenter, prospective, open randomized controlled trial. Patients with acute LVO at 7 Chinese stroke centers participated in the study. The primary efficacy endpoint was defined as a modified thrombolysis in cerebral infarction (mTICI) reperfusion grade ≥ 2 within three passes. The primary safety endpoint comprised any serious adverse device effect, symptomatic intracerebral hemorrhage (sICH), and any serious adverse event (SAE; defined as cerebral palsy or death) within 24 hours after the procedure. The secondary efficacy endpoints consisted of functional independence (modified Rankin Scale score 0-2), procedure duration, and 90-day all-cause mortality. RESULTS: Between January 2014 and August 2016, 67 patients were randomly allocated to the RECO group and 69 patients to the Solitaire FR group. The primary efficacy endpoint (mTICI grade ≥ 2 within three passes) was similar in the two treatment groups (91% vs 87%, respectively, p = 0.5861), and the rate of reperfusion with an mTICI grade 2b/3 was 87% versus 75% (p = 0.1272). There were no serious adverse device effects in any patient. The rates of sICH (1.5% vs 7.2%, p = 0.1027) and SAEs (6.0% vs 1.4%, p = 0.2050) within 24 hours after the procedure were similar in the two treatment groups. There was no significant difference in the rate of functional independence (63% vs 46%, p = 0.0609) or 90-day all-cause mortality (13% vs 23%, p = 0.1848) or in procedure duration (85.39 ± 47.01 vs 89.94 ± 53.34 minutes, p = 0.5986) between the two groups. CONCLUSIONS: The RECO stent retriever is effective and safe as a mechanical thrombectomy device for AIS due to LVO. Clinical trial registration no.: NCT01983644 (clinicaltrials.gov).
Asunto(s)
Isquemia Encefálica/cirugía , Trastornos Cerebrovasculares/complicaciones , Trombolisis Mecánica/instrumentación , Anciano , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/prevención & control , Isquemia Encefálica/etiología , Cateterismo , Angiografía Cerebral , Hemorragia Cerebral/etiología , China , Remoción de Dispositivos/instrumentación , Diseño de Equipo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , StentsRESUMEN
OBJECTIVE: Adjuvant radiation therapy (RT), such as cesium-131 (Cs-131) brachytherapy or stereotactic radiosurgery (SRS), reduces local recurrence (LR) of brain metastases (BM). However, SRS is less efficacious for large cavities, and the delay between surgery and SRS may permit tumor repopulation. Cs-131 has demonstrated improved local control, with reduced radiation necrosis (RN) compared to SRS. This study represents the first comparison of outcomes between Cs-131 brachytherapy and SRS for resected BM. METHODS: Patients with BM treated with Cs-131 and SRS following gross-total resection were retrospectively identified. Thirty patients who underwent Cs-131 brachytherapy were compared to 60 controls who received SRS. Controls were selected from a larger cohort to match the patients treated with Cs-131 in a 2:1 ratio according to tumor size, histology, performance status, and recursive partitioning analysis class. Overall survival (OS), LR, regional recurrence, distant recurrence (DR), and RN were compared. RESULTS: With a median follow-up of 17.5 months for Cs-131-treated and 13.0 months for SRS-treated patients, the LR rate was significantly lower with brachytherapy; 10% for the Cs-131 cohort compared to 28.3% for SRS patients (OR 0.281, 95% CI 0.082-0.949; p = 0.049). Rates of regional recurrence, DR, and OS did not differ significantly between the two cohorts. Kaplan-Meier analysis with log-rank testing showed a significantly higher likelihood of freedom from LR (p = 0.027) as well as DR (p = 0.018) after Cs-131 compared to SRS treatment (p = 0.027), but no difference in likelihood of OS (p = 0.093). Six (10.0%) patients who underwent SRS experienced RN compared to 1 (3.3%) patient who received Cs-131 (p = 0.417). CONCLUSIONS: Postresection patients with BM treated with Cs-131 brachytherapy were more likely to achieve local control compared to SRS-treated patients. This study provides preliminary evidence of the potential of Cs-131 to reduce LR following gross-total resection of single BM, with minimal toxicity, and suggests the need for a prospective study to address this question.
Asunto(s)
Braquiterapia , Neoplasias Encefálicas/secundario , Radioisótopos de Cesio/uso terapéutico , Radiocirugia , Radioterapia Adyuvante , Anciano , Braquiterapia/efectos adversos , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/prevención & control , Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/cirugía , Estudios de Casos y Controles , Hemorragia Cerebral/etiología , Radioisótopos de Cesio/administración & dosificación , Radioisótopos de Cesio/efectos adversos , Femenino , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Masculino , Análisis por Apareamiento , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/prevención & control , Hemorragia Posoperatoria/etiología , Radiocirugia/efectos adversos , Dosificación Radioterapéutica , Estudios Retrospectivos , Convulsiones/etiología , Resultado del TratamientoRESUMEN
OBJECTIVE: The current definition of delayed cerebral ischemia (DCI) is based on clinical characteristics precluding its use in patients with poor-grade subarachnoid hemorrhage (SAH). Additional concepts to evaluate the unconscious patient are required. Invasive neuromonitoring (INM) may allow timely detection of metabolic and oxygenation crises before irreversible damage has occurred. METHODS: The authors present a cohort analysis of all consecutive SAH patients referred to a single tertiary care center between 2010 and 2018. The cohort (n = 190) was split into two groups: one before (n = 96) and one after (n = 94) the introduction of INM in 2014. A total of 55 poor-grade SAH patients were prospectively monitored using parenchymal oxygen saturation measurement and cerebral microdialysis. The primary outcome was the Glasgow Outcome Scale-Extended (GOSE) score after 12 months. RESULTS: With neuromonitoring, the first DCI event was detected earlier (mean 2.2 days, p = 0.002). The overall rate of DCI-related infarctions decreased significantly (from 44.8% to 22.3%; p = 0.001) after the introduction of invasive monitoring. After 12 months, a higher rate of favorable outcome was observed in the post-INM group, compared to the pre-INM group (53.8% vs 39.8%), with a significant difference in the GOSE score distribution (OR 4.86, 95% CI -1.17 to -0.07, p = 0.028). CONCLUSIONS: In this cohort analysis of poor-grade SAH patients, the introduction of INM and the extension of the classic DCI definition toward a functional dimension resulted in an earlier detection and treatment of DCI events. This led to an overall decrease in DCI-related infarctions and an improvement in outcome.
Asunto(s)
Química Encefálica , Daño Encefálico Crónico/prevención & control , Isquemia Encefálica/diagnóstico , Monitorización Neurofisiológica , Oxígeno/análisis , Hemorragia Subaracnoidea/complicaciones , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Aneurisma Roto/complicaciones , Daño Encefálico Crónico/etiología , Isquemia Encefálica/etiología , Isquemia Encefálica/fisiopatología , Isquemia Encefálica/terapia , Infarto Cerebral/etiología , Estudios de Seguimiento , Escala de Consecuencias de Glasgow , Humanos , Aneurisma Intracraneal/complicaciones , Microdiálisis , Persona de Mediana Edad , Estudios Retrospectivos , Centros de Atención Terciaria , Inconsciencia , Adulto JovenRESUMEN
BACKGROUND: The likelihood of neurologically favorable survival declines with prolonged resuscitation. However, the ability of extracorporeal cardiopulmonary resuscitation (ECPR) to modulate this decline is unknown. Our aim was to examine the effects of resuscitation duration on survival and metabolic profile in patients who undergo ECPR for refractory ventricular fibrillation/ventricular tachycardia out-of-hospital cardiac arrest. METHODS: We retrospectively evaluated survival in 160 consecutive adults with refractory ventricular fibrillation/ventricular tachycardia out-of-hospital cardiac arrest treated with the University of Minnesota (UMN) ECPR protocol (transport with ongoing cardiopulmonary resuscitation [CPR] to the cardiac catheterization laboratory for ECPR) compared with 654 adults who had received standard CPR in the amiodarone arm of the ALPS trial (Amiodarone, Lidocaine, or Placebo Study). We evaluated the metabolic changes and rate of survival in relation to duration of CPR in UMN-ECPR patients. RESULTS: Neurologically favorable survival was significantly higher in UMN-ECPR patients versus ALPS patients (33% versus 23%; P=0.01) overall. The mean duration of CPR was also significantly longer for UMN-ECPR patients versus ALPS patients (60 minutes versus 35 minutes; P<0.001). Analysis of the effect of CPR duration on neurologically favorable survival demonstrated significantly higher neurologically favorable survival for UMN-ECPR patients compared with ALPS patients at each CPR duration interval <60 minutes; however, longer CPR duration was associated with a progressive decline in neurologically favorable survival in both groups. All UMN-ECPR patients with 20 to 29 minutes of CPR (8 of 8) survived with neurologically favorable status compared with 24% (24 of 102) of ALPS patients with the same duration of CPR. There were no neurologically favorable survivors in the ALPS cohort with CPR ≥40 minutes, whereas neurologically favorable survival was 25% (9 of 36) for UMN-ECPR patients with 50 to 59 minutes of CPR and 19% with ≥60 minutes of CPR. Relative risk of mortality or poor neurological function was significantly reduced in UMN-ECPR patients with CPR duration ≥60 minutes. Significant metabolic changes included decline in pH, increased lactic acid and arterial partial pressure of carbon dioxide, and thickened left ventricular wall with prolonged professional CPR. CONCLUSIONS: ECPR was associated with improved neurologically favorable survival at all CPR durations <60 minutes despite severe progressive metabolic derangement. However, CPR duration remains a critical determinate of survival.
Asunto(s)
Acidosis Láctica/etiología , Reanimación Cardiopulmonar/métodos , Oxigenación por Membrana Extracorpórea , Hipercapnia/etiología , Hipoxia/etiología , Paro Cardíaco Extrahospitalario/terapia , Apoyo Vital Cardíaco Avanzado , Amiodarona/uso terapéutico , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/prevención & control , Reanimación Cardiopulmonar/efectos adversos , Estudios de Cohortes , Método Doble Ciego , Cardioversión Eléctrica , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Paro Cardíaco Extrahospitalario/complicaciones , Paro Cardíaco Extrahospitalario/mortalidad , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Estudios Retrospectivos , Tasa de Supervivencia , Taquicardia Ventricular/complicaciones , Taquicardia Ventricular/terapia , Factores de Tiempo , Resultado del Tratamiento , Fibrilación Ventricular/complicaciones , Fibrilación Ventricular/terapiaRESUMEN
Previous studies have shown that simvastatin (Sim) has neuroprotective effects in a neonatal model of hypoxia-ischemia (HI)-induced brain injury when administered before but not after HI, pointing to the preconditioning (PC)-like effects of the statin. The present study aimed to gain more insight into the PC-like effect of Sim by studying the role of autophagy and its modulation by mTOR and SIRT1 in neuroprotection. Sim potentiated the autophagy response induced by neonatal HI, as shown by the increased expression of both microtubule-associated protein 1 light chain 3 (LC3) and beclin 1, increased monodansylcadaverine (MDC) labeling, and reduced expression of p62. The autophagy inhibitor 3-methyladenine (3MA) completely blocked the neuroprotective effect of Sim. Two hours after HI, there was a reduction in the activity of mTORC1 and a concomitant increase in that of mTORC2. Sim preconditioning further decreased the activity of mTORC1, but did not affect that of mTORC2. However, 24 h after injury, mTORC2 activity was significantly preserved in Sim-treated rats. Sim preconditioning also prevented the depletion of SIRT1 induced by HI, an effect that was completely blocked by 3MA. These data show that Sim preconditioning may modulate autophagy and survival pathways by affecting mTORC1, mTORC2, and SIRT1 activities. This study provides further preclinical evidence of the PC-like effect of statins in brain tissue, supporting their beneficial effects in improving stroke outcome after prophylactic treatments.
Asunto(s)
Autofagia/efectos de los fármacos , Daño Encefálico Crónico/prevención & control , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Hipoxia-Isquemia Encefálica/tratamiento farmacológico , Fármacos Neuroprotectores/farmacología , Simvastatina/farmacología , Sirtuina 1/efectos de los fármacos , Sirtuina 1/metabolismo , Adenina/análogos & derivados , Adenina/farmacología , Animales , Animales Recién Nacidos , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/patología , Hipoxia-Isquemia Encefálica/complicaciones , Hipoxia-Isquemia Encefálica/patología , Precondicionamiento Isquémico , Diana Mecanicista del Complejo 1 de la Rapamicina/efectos de los fármacos , Diana Mecanicista del Complejo 1 de la Rapamicina/metabolismo , Diana Mecanicista del Complejo 2 de la Rapamicina/efectos de los fármacos , Diana Mecanicista del Complejo 2 de la Rapamicina/metabolismo , Ratas , Ratas Sprague-Dawley , Simvastatina/antagonistas & inhibidoresAsunto(s)
Anestesia General , Trombosis de las Arterias Carótidas/terapia , Sedación Consciente , Infarto de la Arteria Cerebral Media/terapia , Trombolisis Mecánica , Medicina Perioperatoria/tendencias , Anestesia General/efectos adversos , Anestesia General/métodos , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/prevención & control , Trombosis de las Arterias Carótidas/complicaciones , Sedación Consciente/efectos adversos , Sedación Consciente/métodos , Servicios Médicos de Urgencia/métodos , Estudios de Equivalencia como Asunto , Humanos , Infarto de la Arteria Cerebral Media/complicaciones , Trombolisis Mecánica/efectos adversos , Trombolisis Mecánica/métodos , Metaanálisis como Asunto , Medicina Perioperatoria/métodos , Ensayos Clínicos Controlados Aleatorios como AsuntoAsunto(s)
Adyuvantes Anestésicos/administración & dosificación , Pentobarbital/administración & dosificación , Resucitación/métodos , Animales , Asfixia Neonatal/complicaciones , Asfixia Neonatal/terapia , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/prevención & control , Modelos Animales de Enfermedad , Humanos , Macaca mulattaRESUMEN
BACKGROUND: Central pro-inflammatory cytokine (PIC) signal is involved in neurological deficits after transient global ischemia induced by cardiac arrest (CA). The present study was to examine if blocking acid sensing ion channels (ASICs) using amiloride in the Central Nervous System can alleviate neurological deficits after the induction of CA and further examine the participation of PIC signal in the hippocampus for the effects of amiloride. METHODS: CA was induced by asphyxia and then cardiopulmonary resuscitation was performed in rats. Western blot analysis and ELISA were used to determine the protein expression of ASIC subunit ASIC1 in the hippocampus, and the levels of PICs. As noted, it is unlikely that this procedure is clinically used although amiloride and other pharmacological agents were given into the brain in this study. RESULTS: CA increased ASIC1 in the hippocampus of rats in comparison with control animals. This was associated with the increase in IL-1ß, IL-6 and TNF-α together with Caspase-3 and Caspase-9. The administration of amiloride into the lateral ventricle attenuated the upregulation of Caspase-3/Caspase-9 and this further alleviated neurological severity score and brain edema. Inhibition of central IL-6 and TNF-α also decreased ASIC1 in the hippocampus of CA rats. CONCLUSION: Transient global ischemia induced by CA amplifies ASIC1a in the hippocampus likely via PIC signal. Amiloride administered into the Central Nervous System plays a neuroprotective role in the process of global ischemia. Thus, targeting ASICs (i.e., ASIC1a) is suggested for the treatment and improvement of CA-evoked global cerebral ischemia.
Asunto(s)
Canales Iónicos Sensibles al Ácido/metabolismo , Amilorida/uso terapéutico , Hipocampo/metabolismo , Interleucina-6/metabolismo , Ataque Isquémico Transitorio/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/metabolismo , Canales Iónicos Sensibles al Ácido/genética , Amilorida/farmacología , Animales , Asfixia/complicaciones , Daño Encefálico Crónico/tratamiento farmacológico , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/prevención & control , Edema Encefálico/tratamiento farmacológico , Edema Encefálico/etiología , Caspasa 3/biosíntesis , Caspasa 3/genética , Caspasa 9/biosíntesis , Caspasa 9/genética , Evaluación Preclínica de Medicamentos , Hidrazinas/farmacología , Ataque Isquémico Transitorio/etiología , Ataque Isquémico Transitorio/metabolismo , Masculino , Quinoxalinas/farmacología , Ratas Sprague-Dawley , Regulación hacia Arriba/efectos de los fármacosRESUMEN
Successful resuscitation from cardiac arrest results in a post-cardiac arrest syndrome, which can evolve in the days to weeks after return of sustained circulation. The components of post-cardiac arrest syndrome are brain injury, myocardial dysfunction, systemic ischemia/reperfusion response, and persistent precipitating pathophysiology. Pediatric post-cardiac arrest care focuses on anticipating, identifying, and treating this complex physiology to improve survival and neurological outcomes. This scientific statement on post-cardiac arrest care is the result of a consensus process that included pediatric and adult emergency medicine, critical care, cardiac critical care, cardiology, neurology, and nursing specialists who analyzed the past 20 years of pediatric cardiac arrest, adult cardiac arrest, and pediatric critical illness peer-reviewed published literature. The statement summarizes the epidemiology, pathophysiology, management, and prognostication after return of sustained circulation after cardiac arrest, and it provides consensus on the current evidence supporting elements of pediatric post-cardiac arrest care.
Asunto(s)
Reanimación Cardiopulmonar , Paro Cardíaco/rehabilitación , Lesión Renal Aguda/etiología , Lesión Renal Aguda/terapia , Insuficiencia Suprarrenal/etiología , Insuficiencia Suprarrenal/terapia , Anticonvulsivantes/uso terapéutico , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/prevención & control , Cardiomiopatías/etiología , Cardiomiopatías/prevención & control , Fármacos Cardiovasculares/uso terapéutico , Niño , Terapia Combinada , Fluidoterapia , Trastornos del Metabolismo de la Glucosa/etiología , Trastornos del Metabolismo de la Glucosa/terapia , Paro Cardíaco/complicaciones , Paro Cardíaco/epidemiología , Paro Cardíaco/terapia , Humanos , Hipnóticos y Sedantes/uso terapéutico , Hipotermia Inducida , Hipoxia-Isquemia Encefálica/etiología , Hipoxia-Isquemia Encefálica/fisiopatología , Hipoxia-Isquemia Encefálica/rehabilitación , Infecciones/etiología , Inflamación/etiología , Monitoreo Fisiológico , Insuficiencia Multiorgánica/etiología , Insuficiencia Multiorgánica/prevención & control , Bloqueantes Neuromusculares/uso terapéutico , Terapia por Inhalación de Oxígeno , Pronóstico , Daño por Reperfusión/etiología , Daño por Reperfusión/prevención & control , Terapia Respiratoria , Factores de TiempoRESUMEN
Diabetes is a chronic metabolic disease and cerebral ischemia is a serious complication of diabetes. Anti-diabetic therapy mitigates this complication but increases the risk of exposure to recurrent hypoglycemia (RH). We showed previously that RH exposure increases ischemic brain damage in insulin-treated diabetic (ITD) rats. The present study evaluated the hypothesis that increased intra-ischemic acidosis in RH-exposed ITD rats leads to pronounced post-ischemic hypoperfusion via activation of acid-sensing (proton-gated) ion channels (ASICs). Streptozotocin-diabetic rats treated with insulin were considered ITD rats. ITD rats were exposed to RH for 5 days and were randomized into Psalmotoxin1 (PcTx1, ASIC1a inhibitor), APETx2 (ASIC3 inhibitor), or vehicle groups. Transient global cerebral ischemia was induced overnight after RH. Cerebral blood flow was measured using laser Doppler flowmetry. Ischemic brain injury in hippocampus was evaluated using histopathology. Post-ischemic hypoperfusion in RH-exposed rats was of greater extent than that in control rats. Inhibition of ASICs prevented RH-induced increase in the extent of post-ischemic hypoperfusion and ischemic brain injury. Since ASIC activation-induced store-operated calcium entry (SOCE) plays a role in vascular tone, next we tested if acidosis activates SOCE via activating ASICs in vascular smooth muscle cells (VSMCs). We observed that SOCE in VSMCs at lower pH is ASIC3 dependent. The results show the role of ASIC in post-ischemic hypoperfusion and increased ischemic damage in RH-exposed ITD rats. Understanding the pathways mediating exacerbated ischemic brain injury in RH-exposed ITD rats may help lower diabetic aggravation of ischemic brain damage.
Asunto(s)
Bloqueadores del Canal Iónico Sensible al Ácido/uso terapéutico , Canales Iónicos Sensibles al Ácido/fisiología , Acidosis/tratamiento farmacológico , Daño Encefálico Crónico/prevención & control , Isquemia Encefálica/complicaciones , Estenosis Carotídea/complicaciones , Venenos de Cnidarios/uso terapéutico , Diabetes Mellitus Experimental/complicaciones , Hipoglucemia/complicaciones , Hipoglucemiantes/toxicidad , Insulina/toxicidad , Péptidos/uso terapéutico , Venenos de Araña/uso terapéutico , Bloqueadores del Canal Iónico Sensible al Ácido/farmacología , Canales Iónicos Sensibles al Ácido/efectos de los fármacos , Acidosis/etiología , Animales , Daño Encefálico Crónico/etiología , Isquemia Encefálica/fisiopatología , Señalización del Calcio/efectos de los fármacos , Señalización del Calcio/fisiología , Circulación Cerebrovascular , Venenos de Cnidarios/farmacología , Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemia/sangre , Hipoglucemia/inducido químicamente , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Flujometría por Láser-Doppler , Masculino , Péptidos/farmacología , Distribución Aleatoria , Ratas , Ratas Wistar , Recurrencia , Venenos de Araña/farmacologíaRESUMEN
Cerebral vasospasm is one of the deleterious complications after subarachnoid hemorrhage (SAH), leading to delayed cerebral ischemia and permanent neurological deficits or even death. Free radicals and oxidative stress are considered as crucial causes contributing to cerebral vasospasm and brain damage after SAH. Tetramethylpyrazine nitrone (TBN), a derivative of the clinically used anti-stroke drug tetramethylpyrazine armed with a powerful free radical scavenging nitrone moiety, has been reported to prevent brain damage from ischemic stroke. The present study aimed to investigate the effects of TBN on vasospasm and brain damage after SAH. Two experimental SAH models were used, a rat model by endovascular perforation and a rabbit model by intracisternal injection of autologous blood. The effects of TBN on SAH were evaluated assessing basilar artery spasm, neuronal apoptosis, and neurological deficits. TBN treatment significantly attenuated vasospasm, improved neurological behavior functions and reduced the number of apoptotic neurons in both the SAH rats and rabbits. Mechanistically, TBN suppressed the increase in 3-nitrotyrosine and 8-hydroxy-2-deoxyguanosine immuno-positive cells in the cortex of SAH rat brain. Western blot analyses indicated that TBN effectively reversed the altered expression of Bcl-2, Bax and cytochrome C, and up-regulated nuclear factor erythroid-derived 2-like 2 (Nrf2) and hemeoxygenase-1 (HO-1) protein expressions. In the in vitro studies, TBN inhibited H2O2-induced bEnd.3 cell apoptosis and reduced ROS generation. Additionally, TBN alleviated the contraction of rat basilar artery rings induced by H2O2 ex vivo. In conclusion, TBN ameliorated SAH-induced cerebral vasospasm and neuronal damage. These effects of TBN may be attributed to its anti-oxidative stress effect and up-regulation of Nrf2/HO-1.
Asunto(s)
Antioxidantes/uso terapéutico , Estrés Oxidativo/efectos de los fármacos , Pirazinas/uso terapéutico , Hemorragia Subaracnoidea/complicaciones , Vasoespasmo Intracraneal/tratamiento farmacológico , Animales , Apoptosis/efectos de los fármacos , Arteria Basilar/efectos de los fármacos , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/prevención & control , Corteza Cerebral/patología , Modelos Animales de Enfermedad , Radicales Libres/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Hemo Oxigenasa (Desciclizante)/fisiología , Hipocampo/patología , Peróxido de Hidrógeno/farmacología , Contracción Isométrica , Masculino , Factor 2 Relacionado con NF-E2/fisiología , Proteínas del Tejido Nervioso/biosíntesis , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/fisiología , Conejos , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismo , Hemorragia Subaracnoidea/metabolismo , Vasoconstricción , Vasoespasmo Intracraneal/etiologíaRESUMEN
Emerging stroke literature suggests that treatment of experimentally induced stroke with stem cells offered post-stroke neuroprotection via exosomes produced by these cells. Treatment with exosomes has great potential to overcome the limitations associated with cell-based therapies. However, in our preliminary studies, we noticed that the exosomes released from human umbilical cord blood-derived mesenchymal stem cells (MSCs) under standard culture conditions did not improve the post-stroke neurological outcome. Because of this apparent discrepancy, we hypothesized that exosome characteristics vary with the conditions of their production. Specifically, we suggest that the exosomes produced from the cocultures of regular and oxygen-glucose-deprived (OGD) MSCs in vitro would represent the exosomes produced from MSCs that are exposed to ischemic brain cells in vivo, and offer similar therapeutic benefits that the cell treatment would provide. We tested the efficacy of therapy with exosomes secreted from human umbilical cord blood (HUCB)-derived MSCs under in vitro hypoxic conditions on post-stroke brain damage and neurological outcome in a rat model of transient focal cerebral ischemia. We performed the TTC staining procedure as well as the neurological tests including the modified neurological severity scores (mNSS), the modified adhesive removal (sticky-tape), and the beam walking tests before ischemia and at regular intervals until 7 days reperfusion. Treatment with exosomes obtained from the cocultures of normal and OGD-induced MSCs reduced the infarct size and ipsilateral hemisphere swelling, preserved the neurological function, and facilitated the recovery of stroke-induced rats. Based on the results, we conclude that the treatment with exosomes secreted from MSCs at appropriate experimental conditions attenuates the post-stroke brain damage and improves the neurological outcome.